



HAL
open science

Enhancing plasticity of the central nervous system : Drugs, stem cell therapy and neuro-implants

Alice Le Friec, Anne-Sophie Salabert, Carole Davoust, Boris Demain, Christophe Vieu, Laurence Vaysse, Pierre Payoux, Isabelle Loubinoux

► **To cite this version:**

Alice Le Friec, Anne-Sophie Salabert, Carole Davoust, Boris Demain, Christophe Vieu, et al.. Enhancing plasticity of the central nervous system : Drugs, stem cell therapy and neuro-implants. *Neural plasticity*, 2017, 2017, pp.Article ID 2545736. <10.1155/2017/2545736>. <hal-01629177>

HAL Id: hal-01629177

<https://laas.hal.science/hal-01629177v1>

Submitted on 6 Nov 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Enhancing plasticity of the central nervous system : Drugs, stem cell therapy and neuro-implants.

Alice Le Friec¹, Anne-Sophie Salabert^{1,2}, Carole Davoust¹, Boris Demain¹, C Vieu³, Laurence Vaysse¹,
Pierre Payoux^{1,4}, I. Loubinoux¹.

¹ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France

²Radiopharmacy Department, CHU Toulouse, France

³LAAS-CNRS, Université de Toulouse, CNRS, INSA, UPS, Toulouse, France

⁴Nuclear Medicine Department, CHU Toulouse, France

Corresponding author:

Isabelle Loubinoux

UMR1214 – Inserm/UPS – ToNIC

CHU PURPAN

Pavillon Baudot

Place du Dr Baylac

31024 Toulouse Cedex 3

France

Tel.: 33(5) 62 74 61 64

Fax: 33(5) 62 74 61 63

Email: isabelle.loubinoux@inserm.fr

Conflict of interest disclosure

The authors declare that there is no conflict of interest regarding the publication of this paper.

Abstract

Stroke represents the first cause of adult acquired disability. Spontaneous recovery, dependent on endogenous neurogenesis, allows for limited recovery in 50% of patients who remain functionally dependent despite physiotherapy. Here we propose a review of novel drug therapies with strong potential in the clinic. We will also discuss new avenues of stem cell therapy in patients with cerebral lesion. A promising future for the development of efficient drugs to enhance functional recovery after stroke seems evident. These drugs will have to prove efficacy also in severely affected patients. The efficacy of stem cell engraftment has been demonstrated, but will have to prove its potential in restoring tissue function for the massive brain lesions that are most debilitating. New answers may lay in biomaterials, a steadily growing field. Biomaterials should ideally resemble lesioned brain structures in architecture and must be proven to increase functional reconnections within host tissue before clinical testing.

Introduction

Pathologies such as stroke remain chronically debilitating despite scientific advances in the vast field of CNS injury. Following the acute phase, there are no effective treatments available to patients besides physiotherapy.

It is now well-known that various mechanisms of brain plasticity occur after stroke onset, both in the acute phase and beyond [1–6]. They may partially account for the spontaneous recovery of motor function [7]. Therefore, drug treatments have increasingly aimed to enhance these processes in order to improve functional recovery [8].

As for tissue repair of the lesioned area, endogenous neurogenesis does not however produce mature neuronal and glial cells in sufficient number to completely regenerate lesioned CNS tissue [9]. Over the last decades, this observation has led to intense focus on stem cell therapy for the treatment of acute and focal CNS damage produced by pathologies such as stroke, traumatic brain injury and spinal cord injury (SCI). Transplanted stem cells are expected to (i) exert trophic effects on host tissue by secretion of beneficial factors and/or (ii) actually replace lost tissue and establish functional short or long-distance connections with host cells. Numerous neural and non-neural stem cell types have shown promise in experimental rodent models of stroke [10, 11] and non-human primate (NHP) models of SCI [12]. This preclinical evidence has allowed stem cell delivery to be clinically tested for safety and efficacy in the treatment of stroke [13, 14], TBI [15, 16] and SCI [17]. However, stem cell trials for brain repair have yet to show consistent results respective to efficacy and functional improvement in Man [18].

Indeed, when considering stem cell graft within the lesion site, it is important to stress the inhospitable nature of the tissue. Excitotoxicity, inflammatory processes, glial scar formation, growth-inhibiting factors, abnormal tissue structure and loss of extracellular matrix

components render the lesion site unfavorable to neuroblast survival and differentiation [19, 20]. Stem cells grafted close to the brain lesion may die despite immunosuppressant therapy [21].

A promising way to provide endogenous neuroblasts and grafted cells with a suitable microenvironment may consist in the development of biomaterial ECM replacements and “scaffolds” [22]. Biomaterials aiming to mimic the ECM have enhanced tissue reconstruction in models of stroke [23]. They may also be engineered to deliver trophic factors [24] or to guide axonal growth [25]. Implantation of biomaterial has just reached first-in-Man clinical testing in the injured spinal cord [26].

Co-transplantation of biomaterial and stem cells has been successfully tested in preclinical studies for the treatment of stroke in the chronic phase in rodents [27, 28]. Although the translation of such therapies to the clinic presents technical challenges, we believe this technology opens up exciting avenues of treatment for focal chronic brain injury.

Here we propose to review the most recent innovative drug, stem-cell and bio-material based therapies for the treatment of CNS injuries such as those caused by stroke and SCI.

1. Drugs

a. Drugs for axon repair

Central Nervous System axons, unlike those in the Peripheral Nervous system, were long thought to have lost their capacity for regeneration after section. This concept now seems outdated. Many recent studies have revealed the existence of proteins, such as NOGO, within the myelin sheath that are capable of inhibiting axonal growth, and prevent axonal regeneration after a lesion. Drugs targeting these inhibitory proteins, such as anti-NOGOs, have been successfully tested in rodents and primates. Steven Cramer and colleagues conducted a double-blinded placebo controlled pilot study of GSK249320, a monoclonal anti-

MAG (myelin-associated glycoprotein) antibody, in patients presenting a moderate walking disability after stroke (0.5 m/sec on average 5 days after stroke). The drug was administered 24h and 9 days after stroke onset, and was well tolerated at the three doses tested (1, 5 or 15 mg/kg, i.v). Only the 5 mg/kg (n=9) dose significantly improved walking speed against placebo (n=17) in a 112-day period, and recovery was particularly marked in the first 60 days [29]. This result suggests that dose and duration of treatment may be further optimized. Experimental testing in animals also showed that early administration within the first week may be more efficient [30]. Unfortunately, a recent large trial on 134 patients was interrupted for lack of efficacy despite the safety of the humanized monoclonal antibody (Cramer et al. Stroke 2017). However, anti-NOGO or other molecules may prove efficacy of this strategy in the future.

b. Growth factors

Growth factors such as G-CSF (Granulocyte Colony-Stimulating Factor), known to recruit hematopoietic stem cells, have been considered for use in stroke therapy based on the rationale that they possess such beneficial properties in the acute phase of stroke as the inhibition of glutamate secretion, reduction of inflammation, and anti-apoptotic and anti-edema effects, as well as pro-angiogenesis and neurogenesis properties in the chronic phase [31]. However, no functional improvement was evidenced in a cohort of 548 patients [32]. Similar results were found for other growth factors, such as bFGF (basic Fibroblast Growth Factor or Trafermin), known to increase neurite growth. When administered in the acute phase, bFGF caused systemic adverse effects and mortality. The phase II/III trial was interrupted at 286 patients [33]. Another neurotrophic factor, Brain-Derived Neurotrophic Factor, was shown to be toxic. Thus it is not currently feasible to consider the use of such growth factors for therapy after ischemic stroke.

c. Selective Serotonin Re-uptake Inhibitors (SSRI)

Our team in Toulouse has focused on NeuroImaging as a means to develop and adapt biomarker-based therapeutic strategies. We propose candidate biomarkers for (1) use in motor outcome prediction [34–36] and (2) as therapeutic agents with proven efficacy as evaluated by fMRI [37–43]. Recent work in our laboratory, which was confirmed by other teams, has demonstrated that the ipsilesional motor cortex M1 is a key structure of motor recovery, and is thus a suitable target for drug-, stem-cell, and non-invasive brain stimulation-based therapies. Functional activations in the primary sensorimotor cortex may be enhanced by the administration of monoaminergic drugs. Drug-induced hyperactivations have been positively correlated with motor improvement, even in unique doses of treatment. However, this result was elicited in small groups of moderately disabled stroke patients, and work must be extended to more severely affected patients, who respond modestly to interventions. Our group demonstrated, in a double-blind placebo controlled multicentric clinical trial of 118 patients, including heavily affected stroke patients, that fluoxetine (Prozac) treatment significantly improves motor recovery (Fugl-meyer scale and motor NIHSS) when compared to placebo. Functional improvement was observed, and a higher number of patients regained independence in the treatment group (mRS, modified Rankin Score) [44]. In a recent study with another SSRI, a similar result was found along with a 50% reduction in the 3-month National Institutes of Health Stroke Scale compared with the baseline scores. This was achieved in 57 patients in the citalopram and 39 patients in the placebo group (Oskouie NNR 2017). Recommendations for the design of clinical drug studies in stroke have been produced [45]. The Cochrane review reported that while SSRIs may improve patient independence, deficit, neurological status, as well as lessen anxiety and depression, inter-trial heterogeneity limits the drawing of meaningful conclusions. Larger clinical trials are needed to validate fluoxetine as stroke treatment before it can be prescribed routinely in the clinic [46], and must

confirm treatment efficacy as well as determine optimal dose and length of treatment. To this end, phase III trials have been launched in Australia (<http://affinitytrial.org>), Sweden (<http://www.effects.se>) and the United Kingdom (<http://focustrial.org.uk>) [47], and aim to include 6000 patients, 4176 of which have already been enrolled (Focus 3127, Affinity 334, Effect 715). IRSS induce only minor and well-known adverse effects, and are well tolerated in stroke patients. Although clinical evidence of efficacy is pending, the benefit to risk ratio seems for now in favor of SSRIs prescription after ischemic stroke.

When considering the mechanism of action of this antidepressant, it is useful to evoke the historic experiments that first evidenced concomitant firing of neurons in the raphe nucleus during movement, leading Jacobs & Fornal to propose motor facilitation as a primary function of the serotonergic system [48]. It follows that the benefit of IRSS treatment may be further enhanced by physiotherapy. Furthermore, recent studies have described other biological effects of SSRI drugs such as anti-inflammatory properties through microglial repression and reduction of neutrophil infiltration [49, 50], increase in BDNF secretion [51], as well as enhancement of neurogenesis (see next chapter) and neural stem cell survival and differentiation [52, 53], even in aged brain lesioned rats [54]. In line with the neurogenic effect of SSRI, studies have shown that fluoxetine improves declarative memory and increases hippocampal volume in patients suffering from post-traumatic stress disorder [55, 56].

2. Stem cell engraftment

Neurogenesis, defined as the capacity of the brain to produce new neurons, has been evidenced in Man [57] in neurogenic brain regions, namely the dentate gyrus of the hippocampus and in the subventricular zone of the cortex. These niches produce stem cells and progenitor cells, that are capable of migrating to damaged cortical and/or subcortical brain areas and replacing lost neurons in patients after stroke [1, 9, 58, 59]. However, few

neuroblasts survive to reach full neuronal differentiation. Those that do often remain confined to the lesion border and are thus incapable of replacing extensive losses of neuronal tissue. Recent work has shown that as few as 0.2% of lost neurons are replaced [9].

Stem-cell based therapeutic strategies aim to support and/or stimulate endogenous neurogenesis by engraftment of stem cells, most often through intravenous or intracerebral delivery. One benefit of stem cell therapy may be the release of neuroprotective, trophic or immunomodulatory factors by grafted cells. These so-called trophic effects occur rapidly after engraftment and may stimulate endogenous neurogenesis, angiogenesis and neovascularization, as well as reduce apoptosis and inflammation [60]. However, for massive brain injury and severely affected patients, trophic effects will unlikely allow sufficient tissue regeneration. In these cases particularly, engraftment of stem cells with a view to not only provide trophic support, but to also replace damaged neurons and brain tissue could be considered.

The least invasive method of stem cell delivery remains intravenous. This procedure is carried out for the delivery of hematopoietic or mesenchymal stem cells. Clinical trials must meet stringent GMP (Good Manufacturing Practices) norms that regulate the quality and safety of cells for engraftment. These regulations dictate all aspects of cell origin, from the composition of cell culture mediums (which must avoid reliance on products of animal origin), to the cell banks from which the cells are selected, which must be genetically stable and homogenous, and regularly tested for identity, viability and sterility.

- a. Mesenchymal stem cells

- i. Intravenous delivery

Mesenchymal stem cells have the advantage of being relatively easy to isolate and amplify from readily accessible tissue samples. In particular, they may be extracted more easily from

fat tissue than from bone marrow. Allogenic stem cell transplantation is rendered possible by the fact that these cells do not express the Major Histocompatibility Complex (MHC) antigen. Mesenchymal stem cells can be differentiated into many cell types (chondrocytes, osteoblasts, osteocytes, adipocytes, myocytes, tendinocytes...) and possess capacity for migration toward damaged tissue in the brain [61]. Intravenous administration of adult mesenchymal stem cells has proven safe thus far [62–64] and potentially efficient. A recent study found that intravenous delivery of multipotent progenitor cells, although well tolerated, did not produce significant improvement [65]. However, the number of patients included (n = 126, intent-to-treat population) may not have provided sufficient statistical power to show modest effects. Clinical trials to evaluate the efficacy of the approach are ongoing (Resstore trial, principal investigator : Olivier Detante). It is likely that any beneficial properties will result from trophic effects, which may reduce neuroinflammation in the acute phase, and support the neovascularization within the damaged parenchyma.

ii. Intracerebral delivery

A recent phase I/2a american trial has demonstrated the safety of an intracerebral graft of mesenchymal stem cells, genetically engineered to transiently express notch-1, a factor known to drive neuronal differentiation [13]. 18 patients with ischemic brain damage (11 of whom were women), of an average of 61 years old, and presenting a stable and chronic motor deficit, received the graft between 6 and 20 months after injury and were followed for a year (n=16). 2.5, 5 or 10 million SB263 cells produced by SanBio were injected into the peri-infarct. Proof of concept research showed cell survival 1 month after transplantation in cerebrolesioned animals [13]. One serious adverse event was declared (asymptomatic subdural hematoma). NIHSS neurological scale, European stroke scale and Fugl-Meyer scale results evidenced significant improvement of recovery in graft recipients. However, for

ethical reasons, this study was not controlled by a group of patients receiving a control surgical procedure.

b. Intraspinal graft of olfactory ensheathing stem cells

Autologous engraftment of olfactory ensheathing cells, harvested from the olfactory mucosa of 3 chronic medullar injury patients produced a quite spectacular improvement in American Spinal Injury Association class (A to B or C) scores in two patients, and more local enhancement of motricity and sensitivity in the third patient [17]. Though the mechanisms of action of these cells are far from elucidated, it has been suggested that these “support cells” may reduce glial scar formation, rendering the lesion site more permissive to axonal regeneration.

c. Intracerebral graft of neural stem cells

The main challenge in tissue regeneration therapies is not only the replacement of lost neurons, but also the establishment of functional reconnections. In this view, selecting a cell source is difficult.

In a first phase 2 randomized clinical trial led by Kondziolka et al, the feasibility of intracerebral stem cell engraftment in 14 stable stroke patients was demonstrated [66, 67]. Although successfully differentiated into neurons, the hNT2 (LBS-Neurons, Layton Bioscience) stem cell line they used originates from a teratocarcinoma and is no longer authorized for trial in Man due to its extremely abnormal caryotype. The study included a small (n=4) group of control patients, paired for physiotherapy. Six out of eleven PET scans evidenced an improvement of glucose intake at the implantation site (3 injections were performed: above, within and below the lesion site). Improvement of functional recovery was not significant in the treated group compared to controls. Four treated patients, who presented lesions in the non-dominant hemisphere, showed enhanced performance in the figure of Rey test. This suggests improved visuospatial skills and non-verbal memory [68].

A recent phase 1 first-in-man study used the CTX0E03 or ReN001 cell line (ReNeuron) derived from genetically modified embryonic stem cells originating from human fetal neuroepithelium [14]. In order to control the amplification of cells, they used c-mycERT AM technology to drive expression of an oestradiol receptor under tamoxifen (4-OHT) induction (added to culture medium). Cell division is arrested and differentiation into neuronal and glial lineages was induced by removal of tamoxifen and growth factors from the medium. It is important to note that the use of tamoxifen for the treatment of breast cancer in women could restart division of the transplanted cells. For this reason, women were excluded from the protocol. Eleven men presenting a moderate to severe disability were enrolled for perilesional grafting of 2, 5, 10 or 20 million cells 6 to 60 months after stroke onset. Patients did not receive any immunosuppressive therapy. Patients were followed for 2 years as part of this non-controlled trial. No immunological or adverse effects were attributed to the grafted cells. Modest improvements of different motor scales were observed (NIHSS, Barthel index, Ashworth Spasticity Scale for the arm and leg, and a quality of life and health status EuroQoL Five Dimensions questionnaire EQ-5D).

Although the setup of methodologies to control trials with groups of operated-upon but non-grafted patients poses for now unsurmountable technical and ethical difficulties, the true efficacy of stem cell based interventions cannot be fully validated without this condition and larger patient cohorts. Perilesional injection of cells into healthy tissue is often performed in order to optimize stem cell survival. The rapidly occurring trophic effects of this approach is now well established, however true functional replacement of lost cells remains to be solidly demonstrated although difficult to test in humans.

While regenerative medicine strategies aim to replace the lesioned neural tissue by intracerebral engraftment, the lesion site microenvironment is uncondusive to progenitor survival and differentiation due to the destruction of extracellular matrix (ECM) components

which can be replaced or isolated by scar tissue [19, 69]. Effectiveness of therapy is limited as only 5% of grafted cells survive. An exciting solution to this problem may be produced by nanotechnology scaffolds.

3. Neuro-implants

Biomaterials may provide a suitable support for cells, replacing lost extracellular matrix. They may promote cell survival and differentiation, revascularisation and recolonisation of lesioned tissue by glia and endothelium cells from the host. More complex biomimetic materials may also guide axonal growth towards their biological targets, restoring effective and even long-distance connections between damaged and healthy tissues. Where stroke is concerned, research in this innovative field remains currently preclinical.

a. Injectable nanometric biomaterials

i. Nanofibers

Fibrous biomaterials of nanometric dimension were injected in scar tissue in a rat model of medullar lesion. They were composed of peptides that auto-assemble to form fibers and contain epitopes of laminin, an ECM component involved in processes such as cell adhesion. Axons of the descending corticospinal tract and those of the ascending sensory neurons that could not previously cross the fibrous glial scar were able to penetrate the biomaterial and cross the lesion. Importantly, motor recovery was significantly enhanced in treated animals [70]. A biodegradable and biocompatible block copolymer of Poly-lactic-co-glycolic acid and Poly-L-lysine improves functional recovery of rats and non-human primates after a partial and complete lateral hemisection of the thoracic spinal cord [71]. INSPIRE, a clinical trial is ongoing and the safety of this approach in man has been published in one case [26].

ii. Hydrogels

Polymer hydrogels are another candidate biomaterial for the support of grafted cells. For instance, polyglycolic acid (PGA) is often used as it is porous, biodegradable and entirely synthetic, meaning its exact composition can be easily controlled. Park and coll. included neural stem cells in a soluble hydrogel which then polymerizes within the lesion site [72]. They demonstrated convincing tissue reconstruction in a rodent model of ischemic stroke (middle cerebral artery occlusion (MCAo) which produces massive lesions. The biomaterial is conducive to neurite growth, and connections were evidenced between host and grafted cells. Vascularisation, reduction of the glial scar and of monocyte infiltration was also found. This type of approach has shown promising results for sensorimotor and cognitive recovery [73].

iii. Micrometric injectable biomaterials

- Microbeads

Easily injectable micrometric biomaterial beads have also been developed. When injected in a rat model of Parkinson disease, they improved motricity, decreased striatal lesion volume and reduced substantia nigra degeneration [74].

- Structured and guiding biomaterial implants

Our team has proposed a strategy for the long distance bridging of brain regions using biomaterials seeded with neural stem cells, called neuro-implants, in collaboration with LAAS-CNRS (Fig. 1). They are made with PDMS (polydimethylsiloxane), and micro-structured to guide axonal growth in predefined directions (Fig. 2). We have conducted a proof of concept study of the efficacy of neuro-implants compared to implants alone in a rat model of corticostriatal lesion impacting the corticospinal tract, which produces loss of forelimb strength and dexterity [75]. The implants did not increase reactive astrogliosis, scarring or inflammatory responses. They improved survival of grafted cells, their maturation

and partial tissue reconstruction within the lesion site around the implants. Reconstructed tissue around the neuro-implants was vascularized as assessed by the HMPAO radiotracer perfusion with SPECT imaging (Fig 3). In contrast, lesioned tissue without implants evolved in a cystic cavity (Fig 3, red arrows). The increase in number of surviving grafted cells may also have trophic effects on cerebral plasticity, such as growth factor and anti-inflammatory factor secretion [76].




Fig 1: Neuro-implant concept. Guiding scaffolds located in a lesion of the corticospinal tract may improve tissue reconstruction and appropriate direction of regenerated tracts.




Fig. 2: Representative horizontal brain section of the lesioned area under brightfield illumination from *Implants Alone* (A, Scale bar: 1 mm) and *neuro-implants rats* (B). The newly generated tissue was mostly located around the PDMS implants. B: Human neural stem cells were identified by a specific human marker hNCAM or hMTCO2, in combination with a marker (in green) of immature (Nestin) and mature (MAP2) neurons. Low magnification is provided on the left and higher magnifications on the right (scale bars: 100 μ m). Grafted cell neurites were aligned along the grooves of the implant.




Fig. 3: Measurement of cerebral blood flow by nanoSPECT Plus-CT Bioscan with $[^{99m}\text{Tc}]$ -HMPAO. Fifteen minutes after intravenous injection of 50 MBq of $[^{99m}\text{Tc}]$ -HMPAO in the tail vein of Sprague Dawley anesthetized rats, data were acquired during 7 min for SPECT (48 sec and 100 000 cps per projection, image size 276*276*164, 0.1 mm) and 1 min for CT (55 kVp, 500 msec, pitch 0,5, binning 1:4). Following the reconstruction, the CT images were spatially aligned to match the SPECT images. Processing of reconstructed images was performed with the in-house Sysiphe software [77]. Brain implants were identified on CT (blue arrows) and 3D volumes of interest (VOIs) were drawn on either side of the implants (colored rectangles) and symmetric ROIs were drawn on the controlateral side as a control (not shown). Images of two rats 20 days after a corticostriatal lesion and 7 days after implantation of neuro-implants. A,E : CT-scan of brain implants (blue arrows) . One implant was inserted in rat #1 brain and 5 implants in rat #2 brain. B,F : SPECT-CT with HMPAO radiotracer on the area of brain implant. C, G : SPECT-CT with HMPAO radiotracer on the area of brain damage (located behind the implantation zone). We observed major hypoperfusion (red arrow). The presence of implants limited hypoperfusion: for rat #1, -13% in B compared to -25% in C (ROI volume was 0.4 mm^3), for rat #2, -18% in F compared to -57% in G (ROI volume was 1.5 mm^3). H: sagittal view of rat #1. Coronal views B and C are located with grey and red lines. D, I: Rat brain perfused and extracted 3 months after the lesion showing the lesion area where neuro-implants were inserted (grey arrows) or not (red arrows).

Conclusion

In summary, effective drug therapies are gradually becoming available to improve functional recovery after stroke. However, these will unlikely allow spectacular gains in patients with severe brain damage. Many research teams currently strive to demonstrate the efficacy of stem cell transplantation, which has shown promise in many preclinical models of brain injury. Nonetheless, stem cells alone may not repair the most extensive and debilitating lesions. Much hope has arisen from the development of biomaterial scaffolds, a rapidly growing field of research. These would ideally resemble the architecture of the brain in structure [78], and be proven to allow adequate reconnections with host tissue if possible. If not, given the complexity of this approach, they must at least provide a very high benefit before they can be considered in a clinical setting.

Acknowledgement

We thank Carine Pestourie who carried out rat SPECT/CT experiments (Non-Invasive Exploration Service -US006/CREFRE Inserm/UPS/ENVT Toulouse-France). We thank Laurence Vaysse who managed cell culture and immunohistology. This work has been in part supported by a grant from the French National Agency for Research called “Investissements d’Avenir” no. ANR-11-LABEX-0018-01.

References:

1. Lindvall O, Kokaia Z (2015) Neurogenesis following Stroke Affecting the Adult Brain. *Cold Spring Harb Perspect Biol* 7:a019034
2. Murphy TH, Corbett D (2009) Plasticity during stroke recovery: from synapse to behaviour. *Nat Rev Neurosci* 10:861–872
3. Jin K, Wang X, Xie L, Mao XO, Zhu W, Wang Y, Shen J, Mao Y, Banwait S, Greenberg DA (2006) Evidence for stroke-induced neurogenesis in the human brain. *Proc Natl Acad Sci* 103:13198–13202
4. Hermann DM, Chopp M (2012) Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. *Lancet Neurol* 11:369–380
5. Grefkes C, Fink GR (2014) Connectivity-based approaches in stroke and recovery of function. *Lancet Neurol* 13:206–216
6. Liu H, Tian T, Qin W, Li K, Yu C (2016) Contrasting Evolutionary Patterns of Functional Connectivity in Sensorimotor and Cognitive Regions after Stroke. *Front Behav Neurosci* 10:72
7. Alia C, Spalletti C, Lai S, Panarese A, Micera S, Caleo M (2016) Reducing GABAA-mediated inhibition improves forelimb motor function after focal cortical stroke in mice. *Sci Rep* 6:37823
8. Chollet F, Tardy J, Albucher J-F, et al (2011) Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol* 10:123–130
9. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O (2002) Neuronal replacement from endogenous precursors in the adult brain after stroke. *Nat Med* 8:963–970
10. Muñetón-Gómez VC, Doncel-Pérez E, Fernandez AP, Serrano J, Pozo-Rodrigálvarez A, Velloso-Huerta L, Taylor JS, Cardona-Gómez GP, Nieto-Sampedro M, Martínez-Murillo R (2012) Neural differentiation of transplanted neural stem cells in a rat model of striatal lacunar infarction: light and electron microscopic observations. *Front Cell Neurosci*. doi: 10.3389/fncel.2012.00030
11. Vaysse L, Conchou F, Demain B, Davoust C, Plas B, Ruggieri C, Benkaddour M, Simonetta-Moreau M, Loubinoux I (2015) Strength and fine dexterity recovery profiles after a primary motor cortex insult and effect of a neuronal cell graft. *Behav Neurosci* 129:423–434

12. Yamane J, Nakamura M, Iwanami A, et al (2010) Transplantation of galectin-1-expressing human neural stem cells into the injured spinal cord of adult common marmosets. *J Neurosci Res* 1481–89
13. Steinberg GK, Kondziolka D, Wechsler LR, et al (2016) Clinical Outcomes of Transplanted Modified Bone Marrow–Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study. *Stroke* 1817–24
14. Kalladka D, Sinden J, Pollock K, et al (2016) Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. *The Lancet* 388:787–796
15. Kota DJ, Prabhakara KS, van Brummen AJ, Bedi S, Xue H, DiCarlo B, Cox CS, Olson SD (2016) Propranolol and Mesenchymal Stromal Cells Combine to Treat Traumatic Brain Injury: Propranolol and MSCs Combine to Treat TBI. *Stem Cells Transl Med* 5:33–44
16. Cox CS, Hetz RA, Liao GP, et al (2017) Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells: Bone Marrow Cells for TBI. *Stem Cells* 35:1065–1079
17. Tabakow P, Jarmundowicz W, Czapiga B, et al (2013) Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury. *Cell Transplant* 22:1591–1612
18. Boncoraglio GB, Bersano A, Candelise L, Reynolds BA, Parati EA (2010) Stem cell transplantation for ischemic stroke. In: *The Cochrane Collaboration (ed) Cochrane Database Syst. Rev.* John Wiley & Sons, Ltd, p CD007231
19. Burda JE, Sofroniew MV (2014) Reactive Gliosis and the Multicellular Response to CNS Damage and Disease. *Neuron* 81:229–248
20. Coyne TM, Marcus AJ, Woodbury D, Black IB (2006) Marrow Stromal Cells Transplanted to the Adult Brain Are Rejected by an Inflammatory Response and Transfer Donor Labels to Host Neurons and Glia. *Stem Cells* 24:2483–2492
21. Jablonska A, Janowski M, Lukomska B (2013) Different methods of immunosuppression do not prolong the survival of human cord blood-derived neural stem cells transplanted into focal brain-injured immunocompetent rats. *Acta Neurobiol Exp* 73:88–101
22. Boisserand LSB, Kodama T, Papassin J, Auzely R, Moisan A, Rome C, Detante O (2016) Biomaterial Applications in Cell-Based Therapy in Experimental Stroke. *Stem Cells Int* 2016:1–14
23. Ghuman H, Massensini AR, Donnelly J, Kim S-M, Medberry CJ, Badyak SF, Modo M (2016) ECM hydrogel for the treatment of stroke: Characterization of the host cell infiltrate. *Biomaterials* 91:166–181
24. Emerich DF, Silva E, Ali O, Mooney D, Bell W, Yu SJ, Kaneko Y, Borlongan C (2010) Injectable VEGF Hydrogels Produce Near Complete Neurological and Anatomical Protection Following Cerebral Ischemia in Rats. *Cell Transplant* 19:1063–1071
25. Bédier A, Vieu C, Arnauduc F, Sol J-C, Loubinoux I, Vaysse L (2012) Engineering of adult human neural stem cells differentiation through surface micropatterning. *Biomaterials* 33:504–514
26. Theodore N, Hlubek R, Danielson J, Neff K, Vaickus L, Ulich TR, Ropper AE (2016) First Human Implantation of a Bioresorbable Polymer Scaffold for Acute Traumatic Spinal Cord Injury: A Clinical Pilot Study for Safety and Feasibility. *Neurosurgery* 79:E305–E312

27. Bible E, Dell'Acqua F, Solanky B, Balducci A, Crapo PM, Badylak SF, Ahrens ET, Modo M (2012) Non-invasive imaging of transplanted human neural stem cells and ECM scaffold remodeling in the stroke-damaged rat brain by 19F- and diffusion-MRI. *Biomaterials* 33:2858–2871
28. Moshayedi P, Nih LR, Llorente IL, Berg AR, Cinkornpumin J, Lowry WE, Segura T, Carmichael ST (2016) Systematic optimization of an engineered hydrogel allows for selective control of human neural stem cell survival and differentiation after transplantation in the stroke brain. *Biomaterials* 105:145–155
29. Cramer SC, Abila B, Scott NE, Simeoni M, Enney LA, on behalf of the MAG111539 Study Investigators (2013) Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke. *Stroke* 44:1337–1342
30. Cash D, Easton AC, Mesquita M, Beech J, Williams S, Lloyd A, Irving E, Cramer SC (2016) GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. *J Neurol Exp Neurosci* 2:28
31. Abe K, Yamashita T, Takizawa S, Kuroda S, Kinouchi H, Kawahara N (2012) Stem cell therapy for cerebral ischemia: from basic science to clinical applications. *J Cereb Blood Flow Metab* 32:1317–31
32. Bath PM, Sprigg N, England T (2013) Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. *Cochrane Database Syst Rev*. doi: 10.1002/14651858.CD005207.pub4
33. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, Kaste M, Orgogozo J-M, Chamorro A, Desmet A (2002) Fiblast (Trafermin) in Acute Stroke: Results of the European-Australian Phase II/III Safety and Efficacy Trial. *Cerebrovasc Dis* 14:239–251
34. Loubinoux I (2003) Correlation between cerebral reorganization and motor recovery after subcortical infarcts. *NeuroImage* 20:2166–2180
35. Tombari D, Loubinoux I, Pariente J, Gerdelat A, Albucher J-F, Tardy J, Cassol E, Chollet F (2004) A longitudinal fMRI study: in recovering and then in clinically stable sub-cortical stroke patients. *NeuroImage* 23:827–839
36. Loubinoux I, Dechaumont-Palacin S, Castel-Lacanal E, De Boissezon X, Marque P, Pariente J, Albucher J-F, Berry I, Chollet F (2007) Prognostic Value of fMRI in Recovery of Hand Function in Subcortical Stroke Patients. *Cereb Cortex* 17:2980–2987
37. Pariente J, Loubinoux I, Carel C, Albucher J-F, Leger A, Manelfe C, Rascol O, Chollet F (2001) Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. *Ann Neurol* 50:718–729
38. Loubinoux I, Pariente J, Rascol O, Celsis P, Chollet F (2002) Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multi-dose study in healthy subjects. *Neuropsychologia* 18:15–21
39. Loubinoux I, Pariente J, Boulanouar K, Carel C, Manelfe C, Rascol O, Celsis P, Chollet F (2002) A Single Dose of the Serotonin Neurotransmission Agonist Paroxetine Enhances Motor Output: Double-Blind, Placebo-Controlled, fMRI Study in Healthy Subjects. *NeuroImage* 15:26–36

40. Loubinoux I, Tombari D, Pariente J, Gerdelat-Mas A, Franceries X, Cassol E, Rascol O, Pastor J, Chollet F (2005) Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. *NeuroImage* 27:299–313
41. Gerdelat-Mas A, Loubinoux I, Tombari D, Rascol O, Chollet F, Simonetta-Moreau M (2005) Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. *NeuroImage* 27:314–322
42. Loubinoux I, Chollet F (2010) Neuropharmacology in stroke recovery. In: *Brain Repair Stroke*. Cambridge University Press, Cambridge, pp 183–193
43. Tardy J, Pariente J, Leger A, et al (2006) Methylphenidate modulates cerebral post-stroke reorganization. *NeuroImage* 33:913–922
44. Chollet F (2011) Fluoxetine and motor recovery after ischaemic stroke—Author’s reply. *Lancet Neurol* 10:500–501
45. Chollet F, Cramer SC, Steiner C, et al (2014) Pharmacological therapies in post stroke recovery: recommendations for future clinical trials. *J Neurol* 261:1461–1468
46. Mead G, Hsieh C, Lee R, Kutlubaev M, Claxton A, Hankey G, Hackett M (2012) Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. - PubMed - NCBI. *Cochrane Database Syst Rev* 11:CD009286
47. Mead G, Hackett ML, Lundström E, Murray V, Hankey GJ, Dennis M (2015) The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. *Trials* 16:369
48. Jacobs BL, Fornal CA (1997) Serotonin and motor activity. *Curr Opin Neurobiol* 7:820–825
49. Lim C-M, Kim S-W, Park J-Y, Kim C, Yoon SH, Lee J-K (2009) Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. *J Neurosci Res* 87:1037–1045
50. Lee JY, Lee HE, Kang SR, Choi HY, Ryu JH, Yune TY (2014) Fluoxetine inhibits transient global ischemia-induced hippocampal neuronal death and memory impairment by preventing blood–brain barrier disruption. *Neuropharmacology* 79:161–171
51. Lee CH, Park JH, Yoo K-Y, Choi JH, Hwang IK, Ryu PD, Kim D-H, Kwon Y-G, Kim Y-M, Won M-H (2011) Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress. *Exp Neurol* 229:450–459
52. Li W-L, Cai H-H, Wang B, Chen L, Zhou Q-G, Luo C-X, Liu N, Ding X-S, Zhu D-Y (2009) Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. *J Neurosci Res* 87:112–122
53. Taguchi N, Nakayama S, Tanaka M (2012) Fluoxetine has neuroprotective effects after cardiac arrest and cardiopulmonary resuscitation in mouse. *Resuscitation* 83:652–656
54. Buga A-M, Ciobanu O, Bădescu GM, Bogdan C, Weston R, Slevin M, Di Napoli M, Popa-Wagner A (2016) Up-regulation of serotonin receptor 2B mRNA and protein in the peri-infarcted area of aged rats and stroke patients. *Oncotarget* 7:17415

55. Santarelli L, Saxe M, Gross C, et al (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *science* 301:805–809
56. Vermetten E, Vythilingam M, Southwick SM, Charney DS, Bremner JD (2003) Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. *Biol Psychiatry* 54:693–702
57. Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn A-M, Nordborg C, Peterson DA, Gage FH (1998) Neurogenesis in the adult human hippocampus. *Nat Med* 4:1313–17
58. Chen J, Magavi SS, Macklis JD (2004) Neurogenesis of corticospinal motor neurons extending spinal projections in adult mice. *Proc Natl Acad Sci U S A* 101:16357–16362
59. Magavi SS, Leavitt BR, Macklis JD (2000) Induction of neurogenesis in the neocortex of adult mice. *Nature* 405:951–955
60. Dihne M, Hartung H-P, Seitz RJ (2011) Restoring Neuronal Function After Stroke by Cell Replacement: Anatomic and Functional Considerations. *Stroke* 42:2342–2350
61. Li Y, McIntosh K, Chen J, et al (2006) Allogeneic bone marrow stromal cells promote glial–axonal remodeling without immunologic sensitization after stroke in rats. *Exp Neurol* 198:313–325
62. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY (2010) A Long-Term Follow-Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke. *Stem Cells* 28:1099–1106
63. Chen L, Zhang G, Khan AA, Guo X, Gu Y (2016) Clinical Efficacy and Meta-Analysis of Stem Cell Therapies for Patients with Brain Ischemia. *Stem Cells Int* 2016:1–8
64. Prasad K, Sharma A, Garg A, et al (2014) Intravenous Autologous Bone Marrow Mononuclear Stem Cell Therapy for Ischemic Stroke. *Stroke* 45:3618–3624
65. Hess DC, Wechsler LR, Clark WM, et al (2017) Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol* 16:360–368
66. Kondziolka D, Steinberg GK, Wechsler L, et al (2005) Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. *J Neurosurg* 103:38–45
67. Kondziolka D, Wechsler L, Goldstein S, et al (2000) Transplantation of cultured human neuronal cells for patients with stroke. - PubMed - NCBI. *Neurology* 55:565–9
68. Stillely CS, Ryan CM, Kondziolka D, Bender A, DeCesare S, Wechsler L (2004) Changes in cognitive function after neuronal cell transplantation for basal ganglia stroke. *Neurology* 63:1320–1322
69. Silver J, Miller JH (2004) Regeneration beyond the glial scar. *Nat Rev Neurosci* 5:146–156
70. Tysseling-Mattiace VM, Sahni V, Niece KL, Birch D, Czeisler C, Fehlings MG, Stupp SI, Kessler JA (2008) Self-Assembling Nanofibers Inhibit Glial Scar Formation and Promote Axon Elongation after Spinal Cord Injury. *J Neurosci* 28:3814–3823

71. Slotkin JR, Pritchard CD, Luque B, et al (2017) Biodegradable scaffolds promote tissue remodeling and functional improvement in non-human primates with acute spinal cord injury. *Biomaterials* 123:63–76
72. Park KI, Teng YD, Snyder EY (2002) The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. *Nat Biotechnol* 20:1111–1117
73. Jin K, Mao X, Xie L, Galvan V, Lai B, Wang Y, Gorostiza O, Wang X, Greenberg DA (2010) Transplantation of Human Neural Precursor Cells in Matrigel Scaffolding Improves Outcome from Focal Cerebral Ischemia after Delayed Postischemic Treatment in Rats. *J Cereb Blood Flow Metab* 30:534–544
74. Delcroix GJ-R, Garbayo E, Sindji L, Thomas O, Vanpouille-Box C, Schiller PC, Montero-Menei CN (2011) The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats. *Biomaterials* 32:1560–1573
75. Vaysse L, Beduer A, Sol JC, Vieu C, Loubinoux I (2015) Micropatterned bioimplant with guided neuronal cells to promote tissue reconstruction and improve functional recovery after primary motor cortex insult. *Biomaterials* 58:46–53
76. Vaysse L, Labie C, Canolle B, Jozan S, Bédurier A, Arnauduc F, Vieu C, Sol JC, Loubinoux I (2012) Adult human progenitor cells from the temporal lobe: Another source of neuronal cells. *Brain Inj* 26:1636–1645
77. Tensaouti F, Lotterie JA (2008) Sysiphe-Neuroimaging software toolbox. In: *Eur. Soc. Magn. Reson. Med. Biol. 2008 Congr. Oct.* pp 2–4
78. Álvarez Z, Castaño O, Castells AA, Mateos-Timoneda MA, Planell JA, Engel E, Alcántara S (2014) Neurogenesis and vascularization of the damaged brain using a lactate-releasing biomimetic scaffold. *Biomaterials* 35:4769–4781